Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
October 24, 2022 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
October 10, 2022 08:00 ET
|
Morphic Therapeutic
200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations Lymphocyte changes consistent with approved α4β7 inhibitor ...
Global Inflammatory Bowel Disease Treatment Market Is Expected to Reach $34.5 Billion by 2031: Allied Market Research
September 08, 2022 08:59 ET
|
Allied Market Research
Portland, OR, Sept. 08, 2022 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Inflammatory Bowel Disease Treatment Market generated $21.0 billion in 2021,...
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Reverse Stock Split
August 25, 2022 12:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Colorectal Procedure Market to Garner $29.55Bn, Globally, by 2028 Growing at 13.1% CAGR | Exclusive Report by The Insight Partners
August 24, 2022 05:16 ET
|
The Insight Partners
New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Colorectal Procedure Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product,...
First Wave BioPharma, Inc. Announces Private Placement
July 15, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Global Stoma/Ostomy Care Market Report 2022: Market to Reach $4.1 Billion by 2026 - Increasing Obesity Levels Propels Market Growth
May 20, 2022 08:13 ET
|
Research and Markets
Dublin, May 20, 2022 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Stoma/Ostomy Care...
First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
April 27, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Morphic Therapeutic Expands Leadership with Key Appointments in Clinical and Corporate Development
April 06, 2022 08:00 ET
|
Morphic Therapeutic
Dr. Brihad Abhyankar named Vice President of Clinical Development, deeply experienced GI drug development leaderAaron Pelta promoted to Senior Vice President, Business and Corporate Development;...